News Quantified

XENE – xenon pharmaceuticals inc. - common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Canadian Business Journal (Canada)]

-4.9%

BEAT

5.5%

BEAT

-17.4%

BEAT

-3.4%

BEAT

Chardan Capital

Cantor Fitzgerald

Form 4 Xenon Pharmaceuticals For: Nov 28 Filed by: MORTIMER IAN

Form 144 Xenon Pharmaceuticals Filed by: MORTIMER IAN

Form S-8 Xenon Pharmaceuticals

Form 8-K Xenon Pharmaceuticals For: Nov 24

Form SCHEDULE 13G Xenon Pharmaceuticals Filed by: JANUS HENDERSON GROUP PLC

Top News Gainers

3/9 Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.5%

1/14 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 6.2%

1/10 Form 8-K Xenon Pharmaceuticals For: Jan 08 5.6%

12/3 Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference 5.2%

3/2 Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update 5.1%

12/11 Form SC 13D Xenon Pharmaceuticals Filed by: NEUROCRINE BIOSCIENCES INC 4.7%

12/2 Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy 4.1%

3/31 Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19 3.9%

2/4 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 3.0%

1/8 Xenon Pharmaceuticals Inc (NASDAQ: XENE) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. 2.6%

Top News Decliners

12/2 Form 8-K Xenon Pharmaceuticals For: Dec 02 -12.3%

3/11 Form 8-K Xenon Pharmaceuticals For: Mar 11 -8.9%

1/22 Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares -7.0%

3/13 Form 8-K Xenon Pharmaceuticals For: Mar 12 -6.4%

9/25 Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference -4.8%

12/5 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -4.3%

12/5 Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow [Seeking Alpha] -4.3%

2/13 Form SC 13G/A Xenon Pharmaceuticals Filed by: Vivo Opportunity, LLC -4.0%

3/26 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -3.9%

4/28 Form DEF 14A Xenon Pharmaceuticals For: Jun 01 -2.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day